p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation

Biochemical and Biophysical Research Communications

Volumn 383, Issue 4, 2009, Pages 411-416

  Furuhata, A ^a   Kimura, A ^b   Shide, K ^c   Shimoda, K ^c   Murakami, M ^a   Ito, H ^a   Gao, S ^a   Yoshida, K ^a   Tagawa, Y ^a   Hagiwara, K ^d   Takagi, A ^a   Kojima, T ^a   Suzuki, M ^a   Abe, A ^a   Naoe, T ^a   Murate, T ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

ChIP assay; EMSA; JAK2V617F; Myeloproliferative disease; p27Kip1; Promoter analysis; Signal transducer and transcriptions (STATs); Skp2

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 3; JANUS KINASE 2; LUCIFERASE; MESSENGER RNA; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; STAT PROTEIN; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL GROWTH; CHROMATIN IMMUNOPRECIPITATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE MUTATION; MYELOPROLIFERATIVE DISORDER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; INTERLEUKIN-3; JANUS KINASE 2; MICE; MUTATION; PROMOTER REGIONS, GENETIC; S-PHASE KINASE-ASSOCIATED PROTEINS; STAT TRANSCRIPTION FACTORS;

EID: 67349223963     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.04.015     Document Type: Article

References (24)

1. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1779-1790
2. Scott L.M., Scott M.A., Campbell P.J., and Green A.R. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108 (2006) 2435-2437
3. Kota J., Caceres N., and Constantinescu S.N. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 22 (2008) 1828-1840
4. Saharinen P., and Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277 (2002) 47954-47963
5. Pless M., Norga K., Carroll M., Heim M.H., D'Andrea A.D., and Mathey-Prevot B. Receptors that induce erythroid differentiation of Ba/F3 cells: structural requirements and effect on STAT5 binding. Blood 89 (1997) 3175-3185
6. Chu I.M., Hengst L., and Slingerland J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 8 (2008) 253-267
7. Agarwal A., Bumm T.G., Corbin A.S., O'Hare T., Loriaux M., VanDyke J., Willis S.G., Deininger J., Nakayama K.I., Druker B.J., and Deininger M.W. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 112 (2008) 1960-1970
8. Andreu E.J., Lledo E., Poch E., Ivorra C., Albero M.P., Martinez-Climent J.A., Montiel-Duarte C., Rifon J., Perez-Calvo J., Arbona C., Prosper F., and Perez-Roger I. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 65 (2005) 3264-3272
9. Shide K., Shimoda K., Kamezaki K., Kakumitsu H., Kumano T., Numata A., Ishikawa F., Takenaka K., Yamamoto K., Matsuda T., and Harada M. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Leuk. Res. 31 (2007) 1077-1084
10. Nosaka T., Kawashima T., Misawa K., Ikuta K., Mui A.L., and Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 18 (1999) 4754-4765
11. Nakajima K., Yamanaka Y., Nakae K., Kojima H., Ichiba M., Kiuchi N., Kitaoka T., Fukada T., Hibi M., and Hirano T. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 15 (1996) 3651-3658
12. Kato Y., Iwama A., Tadokoro Y., Shimoda K., Minoguchi M., Akira S., Tanaka M., Miyajima A., Kitamura T., and Nakauchi H. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J. Exp. Med. 202 (2005) 169-179
13. Chalandon Y., Jiang X., Christ O., Loutet S., Thanopoulou E., Eaves A., and Eaves C. BCR-ABL-transduced human cord blood cells produce abnormal populations in immunodeficient mice. Leukemia 19 (2005) 442-448
14. Sobue S., Hagiwara K., Banno Y., Tamiya-Koizumi K., Suzuki M., Takagi A., Kojima T., Asano H., Nozawa Y., and Murate T. Transcription factor specificity protein 1 (Sp1) is the main regulator of nerve growth factor-induced sphingosine kinase 1 gene expression of the rat pheochromocytoma cell line, PC12. J. Neurochem. 95 (2005) 940-949
15. Sobue S., Murakami M., Banno Y., Ito H., Kimura A., Gao S., Furuhata A., Takagi A., Kojima T., Suzuki M., Nozawa Y., and Murate T. V-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins. Oncogene 27 (2008) 6023-6033
16. Hulit J., Lee R.J., Li Z., Wang C., Katiyar S., Yang J., Quong A.A., Wu K., Albanese C., Russell R., Di Vizio D., Koff A., Thummala S., Zhang H., Harrell J., Sun H., Muller W.J., Inghirami G., Lisanti M.P., and Pestell R.G. P27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. Cancer Res. 66 (2006) 8529-8541
17. Baker S.J., Rane S.G., and Reddy E.P. Hematopoietic cytokine receptor signaling. Oncogene 26 (2007) 6724-6737
18. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
19. Saharinen P., Vihinen M., and Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14 (2003) 1448-1459
20. Prietzsch H., Brock J., Kleine H.D., Liebe S., and Jaster R. Interferon-alpha inhibits cell cycle progression by Ba/F3 cells through the antagonisation of interleukin-3 effects on key regulators of G(1)/S transition. Cell. Signal. 14 (2002) 751-759
21. Lin Q., Lai R., Chirieac L.R., Li C., Thomazy V.A., Grammatikakis I., Rassidakis G.Z., Zhang W., Fujio Y., Kunisada K., Hamilton S.R., and Amin H.M. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am. J. Pathol. 167 (2005) 969-980
22. de Koning J.P., Soede-Bobok A.A., Ward A.C., Schelen A.M., Antonissen C., van Leeuwen D., Lowenberg B., and Touw I.P. STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene 19 (2000) 3290-3298
23. Davidovich S., Ben-Izhak O., Shapira M., Futerman B., and Hershko D.D. Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast Cancer Res. 10 (2008) R63
24. M. Rosner, M. Hanneder, N. Siegel, A. Valli, C. Fuchs, M. Hengstschlager, Skp2 inversely correlates with p27 and tuberin in transformed cells. Amino Acids (2008).